These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36643309)

  • 1. Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
    Villanueva H; Wells GA; Miller MT; Villanueva M; Pathak R; Castro P; Ittmann MM; Sikora AG; Lerner SP
    Heliyon; 2022 Dec; 8(12):e12570. PubMed ID: 36643309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research.
    DeBord LC; Pathak RR; Villaneuva M; Liu HC; Harrington DA; Yu W; Lewis MT; Sikora AG
    Am J Cancer Res; 2018; 8(8):1642-1660. PubMed ID: 30210932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
    Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
    Front Oncol; 2022; 12():930731. PubMed ID: 36033544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
    Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
    PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L
    Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer.
    Razzaghdoust A; Muhammadnejad S; Parvin M; Mofid B; Zangeneh M; Basiri A
    Iran J Basic Med Sci; 2021 Dec; 24(12):1650-1655. PubMed ID: 35432811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Chicken Embryo Chorioallantoic Membrane (CAM): A Versatile Tool for the Study of Patient-Derived Xenografts.
    Villanueva H; Sikora AG
    Methods Mol Biol; 2022; 2471():209-220. PubMed ID: 35175599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).
    Boughey JC; Suman VJ; Yu J; Santo K; Sinnwell JP; Carter JM; Kalari KR; Tang X; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Hunt KN; Conners AL; Ingle JN; Moyer A; Weinshilboum R; Copland JA; Wang L; Goetz MP
    Clin Cancer Res; 2021 Sep; 27(17):4696-4699. PubMed ID: 34078650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
    Charbonneau M; Harper K; Brochu-Gaudreau K; Perreault A; Roy LO; Lucien F; Tian S; Fortin D; Dubois CM
    Neuro Oncol; 2023 Sep; 25(9):1605-1616. PubMed ID: 36821432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.
    Skowron MA; Sathe A; Romano A; Hoffmann MJ; Schulz WA; van Koeveringe GA; Albers P; Nawroth R; Niegisch G
    Urol Oncol; 2017 Sep; 35(9):544.e11-544.e23. PubMed ID: 28551413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
    Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
    J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy.
    Ossick MV; Ferrari KL; Nunes-Silva I; Denardi F; Reis LO
    Acta Cir Bras; 2020; 34(12):e201901207. PubMed ID: 32049187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.